Davenport & Co’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,500
| Closed | -$5.55K | – | 1081 |
|
|
2023
Q1 | $5.55K | Sell |
1,500
-525
| -26% | -$1.94K | ﹤0.01% | 1018 |
|
|
2022
Q4 | $7.7K | Hold |
2,025
| – | – | ﹤0.01% | 981 |
|
|
2022
Q3 | $16K | Sell |
2,025
-250
| -11% | -$1.98K | ﹤0.01% | 967 |
|
|
2022
Q2 | $48K | Hold |
2,275
| – | – | ﹤0.01% | 956 |
|
|
2022
Q1 | $86K | Sell |
2,275
-150
| -6% | -$5.67K | ﹤0.01% | 1016 |
|
|
2021
Q4 | $136K | Sell |
2,425
-500
| -17% | -$28K | ﹤0.01% | 1015 |
|
|
2021
Q3 | $211K | Buy |
2,925
+75
| +3% | +$5.41K | ﹤0.01% | 965 |
|
|
2021
Q2 | $273K | Sell |
2,850
-125
| -4% | -$12K | ﹤0.01% | 826 |
|
|
2021
Q1 | $440K | Hold |
2,975
| – | – | ﹤0.01% | 557 |
|
|
2020
Q4 | $416K | Buy |
+2,975
| New | +$416K | ﹤0.01% | 569 |
|